Abeona Therapeutics Inc stock is traded at $2.42, with a volume of 3,173,409. It is up +5.68% in the last 24 hours and down -46.46% over the past month. Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Previous Close:
$2.29
Open:
$2.33
24h Volume:
3,173,409
Relative Volume:
0.91
Market Cap:
$149.17M
Revenue:
$5.82M
Net Income/Loss:
$71.18M
P/E Ratio:
2.43
EPS:
$0.9972
Net Cash Flow:
-$84.30M
1W Performance:
-41.97%
1M Performance:
-46.46%
6M Performance:
-57.62%
1Y Performance:
-46.58%
1-Day Range:
$2.09$2.44
1-Week Range:
$2.09$3.62
52-Week Range:
$2.09$7.65
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
646-813-4701Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS